SBIR-STTR Award

Organ-On-Chip Based Assays for Personalized Assessment of Renal Resilience in Aging Patients
Award last edited on: 1/22/20

Sponsored Program
SBIR
Awarding Agency
NIH : NIA
Total Award Amount
$300,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Thomas Neumann

Company Information

Nortis Inc

17280 Woodinville Redmond Road NE Suite B-828
Woodinville, WA 98072
   (206) 414-5631
   info@nortisbio.com
   www.nortisbio.com
Location: Single
Congr. District: 01
County: King

Phase I

Contract Number: 1R43AG066020-01
Start Date: 9/30/19    Completed: 8/31/20
Phase I year
2019
Phase I Amount
$300,000
Age-related kidney diseases, including chronic kidney disease (CKD) and acute kidney injury (AKI) are major health problems and an economic burden worldwide. In the U.S. alone 30 million people are affected by CKD disease, although the vast majority of these individuals are unaware of their condition. A coexisting disease, a new medication, or a surgical procedure can overstress the already compromised kidney resilience and result in AKI, with risk for end stage renal disease and death. Age affects the regenerative capacity of the kidney and is a major risk factor for developing renal disease. However, the degree of kidney resilience in the aged population varies significantly among individuals. Therefore, a diagnostic test that screens for reduced kidney resilience, specifically in older patients, could aid the physician in selecting therapies that are not only efficacious but tolerable by the patient’s kidneys. Currently, such a test does not exist. The proposed project aims to develop a test for assessing the resilience status of a patient’s kidneys. The test involves collecting living urine-derived renal progenitor cells (UPCs) from a patient’s urine sample, growing them into functional kidney tubules in a microfluidic chip, and subjecting the tubules to conditions that challenge kidney resilience. The response of the tubules grown from the patient’s own UPCs provide information about that patient’s kidney resilience and can be used by the physician to optimize treatment choices. Assay readout will include biomarkers of mitochondrial health, reactive oxygen species, lysosomal activity, as well as cell survival, proliferation, and polarity. UPCs are the cell source of choice for building a renal resilience in-vitro model because these cells reflect the degree of kidney resilience/dysfunction of the donor—even when cultured in vitro. The aging signature of UPCs in cell culture, as in vivo, correlates with a loss of stem-cell specific markers and reduced proliferation potential. UPCs from older individuals have been shown to proliferate less than those from younger individuals. Aim 1 of the project is to establish that in-vitro kidney tubules generated from UPCs replicate kidney proximal tubule biomarkers both in young and aged individuals (Milestone 1) and to measure and compare biomarkers for mitochondrial health, reactive oxygen species, lysosomal activity, cell survival, cell proliferation, and cell polarity in chips derived from young and aged individuals (Milestone 2). Aim 2 is to then use these biomarkers for establishing the range of cellular resiliency in kidney chips from young and aged individuals in response to stress conditions, such as transient hypoxia (Milestone 3) and exposure to nephrotoxic compound cisplatin (Milestone 4). The purpose of Aim 2 is to demonstrate significant difference in stress response between kidney chips from healthy young individuals in comparison to aged individuals for at least one of the two tested stressors, hypoxia or cisplatin (Milestone 5). This Phase I project will focus on establishing feasibility for future product development and subsequent clinical studies for regulatory approval.

Public Health Relevance Statement:
Project Narrative The project aims to develop a novel urine test for assessing the health status of a patient’s kidneys. The test involves collecting living kidney cells from the patient’s urine, growing them into functional kidney tubules, and subjecting the tubules to conditions that challenge kidney resilience. The response of the tubules grown from the patient’s cells provide information about the patient’s kidney health and resilience and can be used by the physician to optimize treatment choices.

Project Terms:
Academia; Acute Renal Failure with Renal Papillary Necrosis; Address; Affect; Age; age related; aged; Aging; aging population; Antibiotics; Antineoplastic Agents; base; biological adaptation to stress; Biological Assay; Biological Markers; cell age; Cell Aging; Cell Culture Techniques; Cell Differentiation process; Cell model; Cell Polarity; Cell Proliferation; Cell Survival; cell type; Cells; Cessation of life; Chronic Kidney Failure; Cisplatin; Clinical Research; Collection; Comorbidity; Development; Diabetes Mellitus; Diagnostic tests; Disease; Dose; Drug Industry; Drug toxicity; Economic Burden; End stage renal failure; Epithelial Cells; Event; experience; Exposure to; Functional disorder; Future; Generations; Glomerular capsule structure; Goals; Grant; Harvest; Health; Health Status; Heterogeneity; human old age (65+); Hypertension; Hypoxia; Image; In Vitro; in vitro Assay; in vitro Model; in vivo; Individual; International; Intervention; Kidney; kidney cell; Kidney Diseases; Kidney Function Tests; Life; Measurement; Measures; Microfluidic Microchips; Mitochondria; nephrotoxicity; novel; older patient; Operative Surgical Procedures; organ on a chip; patient tolerability; Patients; personalized diagnostics; Pharmaceutical Preparations; Pharmacology; Pharmacotherapy; Phase; Phenotype; Physicians; Population; predictive test; product development; Proliferating; Proximal Kidney Tubules; Proxy; Reactive Oxygen Species; regenerative; Renal function; Renal tubule structure; Research Personnel; resilience; response; Risk; Risk Factors; Sampling; Services; Severities; Small Business Innovation Research Grant; Source; Specimen; Stem cells; Stress; stress resilience; stressor; Structure; Technology; Testing; Time; Tissues; treatment choice; treatment optimization; Tube; Tubular format

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----